Elevation Oncology Inc.
06/09/2025 | Press release | Distributed by Public on 06/09/2025 06:10
Tender Offer Statement (Form SC14D9C)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Elevation Oncology, Inc.
(Name of Subject Company)
Elevation Oncology, Inc.
(Name of Persons Filing Statement)
COMMON STOCK, PAR VALUE $ 0.0001 PER SHARE
(Title of Class of Securities)
28623U101
(CUSIP Number of Class of Securities)
Tammy Furlong
101 Federal Street, Suite 1900
Boston, Massachusetts
(716) 371-1135
With copies to:
Robert Freedman , Esq.
David Michaels, Esq.
Ryan Mitteness, Esq.
Fenwick and West LLP
401 Union Street, Floor 5
Seattle, WA
(206) 389-4510
(Name, address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
| x | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
The information set forth under Items 1.01, 5.02, 5.07, 7.01 and 9.01 of the Current Report on Form 8-K filed by Elevation Oncology, Inc. on June 9, 2025 (including all exhibits attached thereto) is incorporated herein by reference.
Elevation Oncology Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 09, 2025 at 12:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io